{"id":1089,"date":"2026-09-17T11:23:09","date_gmt":"2026-09-17T11:23:09","guid":{"rendered":"https:\/\/genes2me.com\/blog\/?p=1089"},"modified":"2026-09-17T12:16:22","modified_gmt":"2026-09-17T12:16:22","slug":"apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis","status":"publish","type":"post","link":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/","title":{"rendered":"One gene panel. Three diagnoses sorted out. No guessing."},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

One gene panel. Three diagnoses sorted out. No guessing.<\/strong><\/p>\n\n\n\n

Memories fail. There’s a tremor that refuses to go away. A word that cannot be recalled. For people progressing towards Alzheimer’s, Parkinson’s or dementia, the symptoms are so similar that even experienced doctors are left having to test one gene after another after another \u2014 searching for an answer for months while a family remains in a state of uncertainty.<\/p>\n\n\n\n

The process is known as the diagnostic odyssey, and Genes2Me<\/a> has developed a panel in order to put an end to it.<\/p>\n\n\n\n

The Problem With Testing One Disease at a Time<\/strong><\/p>\n\n\n\n

The problem with neurodegenerative diseases is that they don’t present themselves in a clear way. Early cognitive decline may appear to be Alzheimer’s, or Parkinson’s disease, or a number of other conditions, and the genes responsible for one disorder are often found during the investigation of another. If single-gene tests are carried out one after another, this takes up weeks or even years while each condition is ruled out in turn.<\/p>\n\n\n\n

Is there a smarter method? Yes, test all the relevant factors at once using a single blood sample.<\/p>\n\n\n\n

Meet the APD NGS Panel<\/strong><\/p>\n\n\n\n

The Alzheimer Parkinson Dementia panel<\/a><\/strong> produced by Genes2Me is an NGS assay<\/a><\/strong> based on hybridization which has been designed specifically to achieve this objective \u2013 offering a comprehensive analysis, delivering quick results, and being developed for use in the clinic rather than just on the laboratory bench.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

What’s under the hood:<\/strong><\/p>\n\n\n\n

\u2022  139 clinically relevant genes, spanning ~101 gene families<\/p>\n\n\n\n

\u2022  Whole coding sequence (CDS) coverage \u2014 no shortcuts, no missed hotspots<\/p>\n\n\n\n

\u2022  The target size is 0.39 Mb for high depth and a fast turnaround.<\/p>\n\n\n\n

\u2022  Detects SNVs, InDels and CNVs \u2014 the mutation types that matter most<\/p>\n\n\n\n

\u2022  Runs from a simple blood sample \u2014 no invasive procedures<\/p>\n\n\n\n

Numbers That Back Up Every Report<\/strong><\/p>\n\n\n\n

The quality of a panel depends on the data available. Performance of the APD assay (on the Illumina platform):<\/p>\n\n\n\n

Metric Result<\/span><\/p>\n\n\n\n

\u2022  Coverage uniformity – >99%<\/p>\n\n\n\n

\u2022  Reproducibility – 97%<\/p>\n\n\n\n

\u2022  Sensitivity – 97.2%<\/p>\n\n\n\n

\u2022  On-target ratio – >78%<\/p>\n\n\n\n

The translation provides complete and consistent coverage of all 139 genes, which means that laboratories are able to give definite answers rather than having to say ‘insufficient coverage, please re-test’.<\/p>\n\n\n\n

Why It Matters, Beyond the Spec Sheet<\/strong><\/p>\n\n\n\n

There is one panel and one report, making a real difference to those who need it:<\/p>\n\n\n\n

\u2022     Faster answers \u2014 replace sequential single-gene tests with one comprehensive run<\/p>\n\n\n\n

\u2022     Family peace of mind \u2014 clearer risk insight for relatives of early-onset or familial cases<\/p>\n\n\n\n

\u2022    Smarter care planning \u2014 many next-gen therapies are now genotype-specific, so knowing the gene matters<\/p>\n\n\n\n

\u2022     Less cost, less waiting \u2014 one blood draw beats months of trial-and-error testing<\/p>\n\n\n\n

Part of a Bigger Story<\/strong><\/p>\n\n\n\n

The APD panel is not an isolated offering; it is part of Genes2Me’s Targeted Disorders range, which also includes our Cardiovascular NGS Assay panel<\/a> (357 genes) and Neuromuscular NGS Assay Panel<\/a> (497 genes). All of these panels have the same DNA \u2014 though that’s a bit of a pun.<\/p>\n\n\n\n

\u2022      Platform-agnostic \u2014 runs on Illumina and other major sequencers<\/p>\n\n\n\n

\u2022     CE-IVD certified<\/a> \u2014 validated manufacturing, validated quality<\/p>\n\n\n\n

\u2022     Powered by Cliseq Interpreter<\/a><\/strong> \u2014 our FASTQ-to-report bioinformatics engine, cloud or on-site<\/p>\n\n\n\n

The Takeaway<\/strong><\/p>\n\n\n\n

With the global population getting older, the number of cases of Alzheimer’s, Parkinson’s and dementia will only increase \u2013 and diagnostic laboratories must become quicker than the rise in disease cases. A comprehensive and validated NGS panel such as APD is not only a superior test; it also represents a better approach to diagnosis since it is based on how patients actually present rather than on the way diseases are neatly categorised in a textbook.<\/p>\n\n\n\n

If your lab wants to stop using fragmented single-gene testing and instead go with a single definite answer, then the APD NGS panel is the one to choose.<\/p>\n","protected":false},"excerpt":{"rendered":"

One gene panel. Three diagnoses sorted out. No guessing. Memories fail. There’s a tremor that refuses to go away. A word that cannot be recalled.…<\/p>\n","protected":false},"author":1,"featured_media":1097,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1,215,214],"tags":[503,505,504,506],"yoast_head":"\nAPD NGS Panel: One Gene Test for Alzheimer's, Parkinson's & Dementia<\/title>\n<meta name=\"description\" content=\"One blood sample, 139 genes, one report \u2014 Genes2Me's APD NGS Panel replaces months of single-gene testing for Alzheimer's, Parkinson's and dementia diagnosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"APD NGS Panel: One Gene Test for Alzheimer's, Parkinson's & Dementia\" \/>\n<meta property=\"og:description\" content=\"One blood sample, 139 genes, one report \u2014 Genes2Me's APD NGS Panel replaces months of single-gene testing for Alzheimer's, Parkinson's and dementia diagnosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-17T11:23:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-17T12:16:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/09\/01-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1448\" \/>\n\t<meta property=\"og:image:height\" content=\"1086\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Genes2Me\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Genes2Me\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"contentUrl\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"width\":150,\"height\":69,\"caption\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\"},\"image\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/genes2me.com\/blog\/#website\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"description\":\"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome\",\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/genes2me.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/\",\"url\":\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/\",\"name\":\"APD NGS Panel: One Gene Test for Alzheimer's, Parkinson's & Dementia\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#website\"},\"datePublished\":\"2026-09-17T11:23:09+00:00\",\"dateModified\":\"2026-09-17T12:16:22+00:00\",\"description\":\"One blood sample, 139 genes, one report \u2014 Genes2Me's APD NGS Panel replaces months of single-gene testing for Alzheimer's, Parkinson's and dementia diagnosis.\",\"breadcrumb\":{\"@id\":\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/genes2me.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"One gene panel. Three diagnoses sorted out. No guessing.\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/\"},\"author\":{\"name\":\"Genes2Me\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\"},\"headline\":\"One gene panel. Three diagnoses sorted out. No guessing.\",\"datePublished\":\"2026-09-17T11:23:09+00:00\",\"dateModified\":\"2026-09-17T12:16:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/\"},\"wordCount\":670,\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"keywords\":[\"Alzheimer Parkinson Dementia panel\",\"APD NGS Panel\",\"neurodegenerative disease gene panel\",\"Parkinson's disease genetic testing\"],\"articleSection\":[\"Dignostic Solution\",\"Next Generation Sequencing\",\"NGS Assays\"],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\",\"name\":\"Genes2Me\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"caption\":\"Genes2Me\"},\"description\":\"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.\",\"sameAs\":[\"https:\/\/www.genes2me.com\/\"],\"url\":\"https:\/\/genes2me.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"APD NGS Panel: One Gene Test for Alzheimer's, Parkinson's & Dementia","description":"One blood sample, 139 genes, one report \u2014 Genes2Me's APD NGS Panel replaces months of single-gene testing for Alzheimer's, Parkinson's and dementia diagnosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/","og_locale":"en_US","og_type":"article","og_title":"APD NGS Panel: One Gene Test for Alzheimer's, Parkinson's & Dementia","og_description":"One blood sample, 139 genes, one report \u2014 Genes2Me's APD NGS Panel replaces months of single-gene testing for Alzheimer's, Parkinson's and dementia diagnosis.","og_url":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/","og_site_name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","article_published_time":"2026-09-17T11:23:09+00:00","article_modified_time":"2026-09-17T12:16:22+00:00","og_image":[{"width":1448,"height":1086,"url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/09\/01-1.png","type":"image\/png"}],"author":"Genes2Me","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Genes2Me","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/genes2me.com\/blog\/#organization","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","url":"https:\/\/genes2me.com\/blog\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","contentUrl":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","width":150,"height":69,"caption":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems"},"image":{"@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"WebSite","@id":"https:\/\/genes2me.com\/blog\/#website","url":"https:\/\/genes2me.com\/blog\/","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","description":"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome","publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genes2me.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/","url":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/","name":"APD NGS Panel: One Gene Test for Alzheimer's, Parkinson's & Dementia","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/#website"},"datePublished":"2026-09-17T11:23:09+00:00","dateModified":"2026-09-17T12:16:22+00:00","description":"One blood sample, 139 genes, one report \u2014 Genes2Me's APD NGS Panel replaces months of single-gene testing for Alzheimer's, Parkinson's and dementia diagnosis.","breadcrumb":{"@id":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/genes2me.com\/blog\/"},{"@type":"ListItem","position":2,"name":"One gene panel. Three diagnoses sorted out. No guessing."}]},{"@type":"Article","@id":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/#article","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/"},"author":{"name":"Genes2Me","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa"},"headline":"One gene panel. Three diagnoses sorted out. No guessing.","datePublished":"2026-09-17T11:23:09+00:00","dateModified":"2026-09-17T12:16:22+00:00","mainEntityOfPage":{"@id":"https:\/\/genes2me.com\/blog\/apd-ngs-panel-alzheimer-parkinson-dementia-diagnosis\/"},"wordCount":670,"publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"keywords":["Alzheimer Parkinson Dementia panel","APD NGS Panel","neurodegenerative disease gene panel","Parkinson's disease genetic testing"],"articleSection":["Dignostic Solution","Next Generation Sequencing","NGS Assays"],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa","name":"Genes2Me","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","caption":"Genes2Me"},"description":"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.","sameAs":["https:\/\/www.genes2me.com\/"],"url":"https:\/\/genes2me.com\/blog\/author\/admin\/"}]}},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/1089"}],"collection":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/comments?post=1089"}],"version-history":[{"count":4,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/1089\/revisions"}],"predecessor-version":[{"id":1098,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/1089\/revisions\/1098"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media\/1097"}],"wp:attachment":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media?parent=1089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/categories?post=1089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/tags?post=1089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}